Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Eli Lilly And Co — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 6.4× iShares Core MSCI Emerging Markets ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Eli Lilly And Co for 93 Days on average.
| IEMG | LLY | |
|---|---|---|
Market Cap | $162.00B | $1.04T |
Volume | 13,446,151 | 3,064,878 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $1.28K |
52-Week Low | $64.22 | $799.57 |
Typical Hold Time | 57 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG is trading at $80.50, down 1.88% for the day amid bearish technical signals. The ETF shows strong emerging markets exposure with 39% technology sector weighting and has delivered significant outperformance versus peers over the past year. Recent news highlights IEMG's role in portfolio diversification strategies and its competitive position against other emerging markets ETFs.
The outlook remains cautious given bearish technical indicators, though emerging markets flows are at record levels. Key opportunities include continued EM outperformance and technology exposure, while risks involve concentration concerns and higher volatility compared to developed market alternatives. The 0.09% expense ratio provides cost efficiency for long-term EM exposure.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
